Fresenius Medical Care AG & Co. (Pref) (ETR:FME) has been assigned a €90.00 ($107.14) target price by stock analysts at Independent Research in a research note issued to investors on Thursday. The firm presently has a “neutral” rating on the stock. Independent Research’s target price points to a potential upside of 2.06% from the company’s previous close.

Other research analysts have also issued reports about the stock. JPMorgan Chase & Co. set a €95.10 ($113.21) price objective on shares of Fresenius Medical Care AG & Co. (Pref) and gave the stock a “buy” rating in a report on Wednesday, October 11th. Goldman Sachs Group set a €97.00 ($115.48) price objective on shares of Fresenius Medical Care AG & Co. (Pref) and gave the stock a “buy” rating in a report on Friday, September 29th. Berenberg Bank set a €95.60 ($113.81) price objective on shares of Fresenius Medical Care AG & Co. (Pref) and gave the stock a “buy” rating in a report on Tuesday, September 19th. Morgan Stanley set a €90.00 ($107.14) price objective on shares of Fresenius Medical Care AG & Co. (Pref) and gave the stock a “buy” rating in a report on Friday, September 15th. Finally, Kepler Capital Markets set a €95.00 ($113.10) price objective on shares of Fresenius Medical Care AG & Co. (Pref) and gave the stock a “buy” rating in a report on Thursday, November 2nd. Ten equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of €90.17 ($107.34).

Shares of Fresenius Medical Care AG & Co. (ETR:FME) opened at €88.18 ($104.98) on Thursday. Fresenius Medical Care AG & Co. has a one year low of €73.87 ($87.94) and a one year high of €89.22 ($106.21). The stock has a market cap of $27,130.00 and a price-to-earnings ratio of 21.61.

COPYRIGHT VIOLATION NOTICE: This news story was published by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2018/01/04/fresenius-medical-care-ag-90-00-price-target-at-independent-research.html.

About Fresenius Medical Care AG & Co. (Pref)

Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services. It offers dialysis treatment, and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized ESRD patients and for patients suffering from acute kidney failure.

Analyst Recommendations for Fresenius Medical Care AG & Co. (Pref) (ETR:FME)

Receive News & Ratings for Fresenius Medical Care AG & Co. (Pref) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. (Pref) and related companies with MarketBeat.com's FREE daily email newsletter.